TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12959287
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (155 mg rac‐hydroxychloroquine)
Study: 3040923
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (CAV and VP-16/cisplatin for six cycles)
Study: 3040923
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (three cycles of CAV followed by three of VP-16/cisplatin)
Study: 22500385
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Chinese medicine)
Study: 17591031
Drug: d4T40 arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d4T40 arm (stavudine 40 mg twice daily)
Study: 17591031
Drug: d4T30 arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d4T30 arm (stavudine 30 mg twice daily)
Study: 29248604
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy intervention (group 3)
Study: 27491025
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus reduced-dose cyclosporine (EVR group)
Study: 27491025
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil plus standard-dose cyclosporine (STD group)
Study: 24631948
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (platinum-based, primarily single-agent carboplatin)
Study: 20729740
Drug: Pegylated-interferon and
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated-interferon and ribavirin treatment
Study: 8989060
Drug: Salm-1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salm-1 (50 micrograms of salmeterol, single dose)
Study: 8989060
Drug: Salm-2 (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salm-2 (regular treatment with salmeterol for 1 week)
Study: 8989060
Drug: Plac-1 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plac-1 (single dose of placebo)
Study: 8989060
Drug: Plac-2 (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plac-2 (regular treatment with placebo for 1 week)
Study: 1455910
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of vaccine
Study: 1455910
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of vaccine
Study: 1455910
Drug: 1000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 micrograms of vaccine
Study: 1455910
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of vaccine
Study: 6365236
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg tablet
Study: 6365236
Drug: Isoconazole 300
Normalized name: Isoconazol
DrugBank: Isoconazole (DB08943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoconazole 300 mg tablets (2 tablets)
Study: 28830742
Drug: Valacyclovir (1.5G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (1.5G twice daily for 16 weeks)
Study: 17920357
Drug: High clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High clopidogrel loading dose (>300 mg)
Study: 17920357
Drug: Standard clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clopidogrel loading dose (300 mg)
Study: 12761725
Drug: Surgical therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapies (artificial sphincter procedures and dynamic graciloplasty)
Study: 10761756
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 day 1, etoposide 120 mg/m2 day 1‐3 (bolus therapy)
Study: 10761756
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of carboplatin 100 mg/m2/week for six weeks (infusional therapy)
Study: 8968699
Drug: Test foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test foods producing a higher insulin response
Study: 1598096
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (t-PA) (100 mg)
Study: 19473596
Drug: Deferiprone tablet
Normalized name: Deferiprone Tablets
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone tablet (GPO‐L‐ONE, 500 mg, 3 tablets)
Study: 17460145
Drug: Azathioprine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (75 to 100 mg/d)
Study: 17273657
Drug: Oral polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polymyxin (2.5 mg/kg in 4 daily doses for 7 days)
Study: 17273657
Drug: Oral polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polymyxin
Study: 8795324
Drug: Ondansetron alone
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron alone (4 mg bolus and 0.13 mg.ml‐1 in the morphine solution)
Study: 8795324
Drug: Droperidol alone
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol alone (1.25 mg bolus and 0.05 mg.ml‐1 in the morphine solution)
Study: 8795324
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ondansetron and droperidol)
Study: 1352331
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate topically and acetazolamide 125 mg orally
Study: 31569780
Drug: Comprehensive non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive non-surgical periodontal therapy (test group; n = 20)
Study: 27053715
Drug: Zonisamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (300 mg/d)
Study: 23428763
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of levobupivacaine
Study: 23428763
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of levobupivacaine plus 8 mg of lornoxicam
Study: 23428763
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of levobupivacaine plus 8 mg of lornoxicam and 8 mg of morphine
Study: 20698715
Drug: Erigeron breviscapus
Normalized name: ERIGERON CANADENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erigeron breviscapus (EBHM) extract, 2 tablets three times a day for 6 months
Study: 20698715
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 tablets three times a day for 6 months
Study: 15634721
Drug: 1-wk GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-wk GH replacement therapy (9.5 microg/kg.d)
Study: 12890208
Drug: TL01 phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL01 phototherapy and topical calcipotriol cream (50 microg g(‐1))
Study: 12890208
Drug: TL01 phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL01 phototherapy and topical emollient as placebo
Study: 30470568
Drug: Duloxetine 60mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60mg/day + usual analgesic regimens
Study: 30470568
Drug: Usual analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual analgesic regimens (morphine±acetaminophen±gabapentin)
Study: 2699653
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg metoclopramide
Study: 2699653
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg metoclopramide
Study: 2699653
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of cisplatin (70-100 mg/m2) or ethylenediamine platinum II malonate (800-900 mg/m2)
Study: 2699653
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of metoclopramide
Study: 27902522
Drug: Topical use
Normalized name: Psoralens for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical use of Petroselinum crispum (parsley)
Study: 18990368
Drug: Antagonist multiple-dose
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist multiple-dose protocol (n = 45)
Study: 17175305
Drug: Calcineurin inhibitor-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor-free (CNI) protocol
Study: 17175305
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (tacrolimus, prednisone, mycophenolate mofetil)
Study: 16464205
Drug: Pharmaceutical interventions;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical interventions; compliance with economic evaluation guidance
Study: 16464205
Drug: Modeling approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modeling approach for pharmaceuticals; compliance with economic evaluation guidance
Study: 2439815
Drug: Bopindolol 4
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 4 mg
Study: 2439815
Drug: Bopindolol 8
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 8 mg
Study: 27269306
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg with 50% oxygen inhalation (group H)
Study: 27269306
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg/kg with normal air inhalation (group N)
Study: 25224360
Drug: eBST ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: eBST ≥ 11.4 ng/ml
Study: 22571978
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin levels in men with nonamnestic or amnestic MCI
Study: 22571978
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin levels in women with amnestic MCI
Study: 22571978
Drug: APOE ε4
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APOE ε4 genotype influence on insulin levels
Study: 19727797
Drug: L(-)-menthol (0.01%)
Normalized name: menthol 0.01 MG/MG
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L(-)-menthol (0.01%)
Study: 19727797
Drug: Orange-flavoured placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange-flavoured placebo solution
Study: 18922850
Drug: Hyperbaric articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric articaine 84 mg
Study: 18922850
Drug: Plain articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain articaine 84 mg
Study: 16268751
Drug: General guideline
Approvals — FDA: no, EMA: no, PMDA: no
Description: General guideline implementation (education about guideline‐based drug recommendations)
Study: 2354690
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron supplements (18-20 mg iron/d) containing haem iron and non-haem iron
Study: 2354690
Drug: Low-dose iron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iron supplements (18-20 mg iron/d) containing non-haem iron only
Study: 2354690
Drug: All low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All low-dose iron supplements
Study: 2354690
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of the supplements
Study: 6781157
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with beta-receptor blocker propranolol, alone or in combination with dihydralazine and/or hydrochlorothiazide for 8 years.
Study: 31464577
Drug: Intradiscal platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal platelet-rich plasma (PRP) injections
Study: 17334144
Drug: Topical negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative pressure
Study: 15728930
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 80 ppm for 72 hours
Study: 15728930
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for pulmonary tuberculosis
Study: 11849632
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (Triphasil)
Study: 10516746
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment (698 patients)
Study: 10516746
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment in patients >/=60 years
Study: 10516746
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment in patients <60 years
Study: 10516746
Drug: Conventional combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional combined chemotherapy in patients >/=60 years
Study: 8592718
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) referral
Study: 8592718
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy implementation within 1 month of back injury
Study: 8592718
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of physical therapy
Study: 2013419
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily with NSAID treatment
Study: 2013419
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily without NSAID treatment
Study: 7036300
Drug: No other
Approvals — FDA: no, EMA: no, PMDA: no
Description: No other treatment (Control)
Study: 30716200
Drug: Second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line chemotherapy (2L CT)
Study: 27085870
Drug: Zolpidem (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (12.5 mg at 2300) and Nabilone (3 mg at 0900 and 1800)
Study: 27085870
Drug: Zolpidem (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (12.5 mg at 2300)
Study: 22453547
Drug: 7.5% CO(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% CO(2) inhalation
Study: 19814838
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (55.9‐61.0 g/d on average)
Study: 10409598
Drug: High-hormone phase
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-hormone phase (progesterone/estrogen)
Study: 10409598
Drug: Low-hormone phase
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-hormone phase (placebo)
Study: 7672489
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin therapy
Study: 7043728
Drug: Diflunisal 1
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal 1 g daily
Study: 29096671
Drug: Reactive focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive focal drug administration (RFDA) using dihydroartemisinin‐piperaquine (DHAP)
Study: 26065506
Drug: 1% chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chloramphenicol eye ointment
Study: 26065506
Drug: 2.5% povidone-iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% povidone-iodine ophthalmic solution
Study: 23521128
Drug: IT therapy
Normalized name: Salicylic Acid 2% Topical application Cream [STRI-DEX FRUIT THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT therapy responses
Study: 20646083
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg of Wheat Extract Oil (WEO)
Study: 18821119
Drug: 1% pramoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pramoxine hydrochloride lotion applied twice daily for 4 weeks
Study: 17892995
Drug: Cangrelor with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor with half-dose t-PA
Study: 17892995
Drug: Full-dose t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose t-PA
Study: 17113442
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg prednisolone intramuscularly immediately after surgery
Study: 17113442
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg prednisolone and diclofenac intramuscularly immediately after surgery
Study: 17113442
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline solution (control group)
Study: 11110934
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (RT)
Study: 8958363
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg orally daily
Study: 1526735
Drug: Intravenous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous epinephrine infusion (1 microgram/hr)
Study: 25882384
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (AT/RT)
Study: 19317379
Drug: Ramelteon, 8
Normalized name: Ramelteon, 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon, 8 mg
Study: 19317379
Drug: Zolpidem, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem, 10 mg (positive control)
Study: 15554771
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 600 mg/day b.i.d. for 5 days
Study: 11672449
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy with transdermal oestradiol (50 microg/24 h patch or 1 mg/day gel) combined with oral dihydrogesterone (10 mg/day for 12 days/month, days 19-30).
Study: 29804377
Drug: LAM and
Normalized name: Alprazolam and propranolol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM and ADV combination therapy
Study: 28044367
Drug: 1% anthralin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% anthralin ointment
Study: 17399814
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of simvastatin daily (n=40)
Study: 17262124
Drug: Chemical disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemical disinfection (immersion in 100 ppm chloride solution)
Study: 1301847
Drug: Compound Salvia
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Salvia tablet (CST)
Study: 3927708
Drug: Aerosolized edetate
Normalized name: EDETATE
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized edetate sodium plus oral tetracycline twice daily for three months
Study: 3927708
Drug: Placebo aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol plus oral tetracycline for three months
Study: 29721732
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem 2% ointment
Study: 26496621
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (AndroGel® 1.62%)
Study: 23568851
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of lecithin before surgery
Study: 16803913
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (taught oral examination skills)
Study: 16803913
Drug: E1 (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1 (initial oral examination)
Study: 16803913
Drug: E2 (subsequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (subsequent oral examination)
Study: 29244208
Drug: Joint gaming
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint gaming on a tablet
Study: 23688265
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) combined with deferiprone (DFP) at 75 mg/kg/day
Study: 23688265
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) monotherapy at 50-60 mg/kg 12-24 hr/day sc or iv 7 times weekly
Study: 12714435
Drug: High combined
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High combined antibody response
Study: 12714435
Drug: High combined
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High combined antibody response (adjusted for age and CHD risk factors)
Study: 12714435
Drug: Combined antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibody response
Study: 12410369
Drug: Acupuncture (AP)
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (AP) treatments
Study: 12410369
Drug: Placebo acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acupuncture (AP) treatments